Basic Information
| LncRNA/CircRNA Name | HOXA-AS2 |
| Synonyms | NA |
| Region | GRCh38_7:27107777-27134302 |
| Ensemble | ENSG00000253552 |
| Refseq | NR_122069 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | acute myeloid leukemia |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot etc. |
| Sample | bone marrow samples, cell lines (HEK-293T,HL-60, U937, THP-1, OCI-AML3,NB4, Kasumi-1 and K562) |
| Expression Pattern | up-regulated |
| Function Description | This study showed that HOXA-AS2 was overexpressed in AML patients. In addition, the increased HOXA-AS2 expression was correlated with higher white blood cell and bone marrow blast counts, unfavorable karyotype classification, more measurable residual disease positivity and earlier death.There was also a tendency towards inferior survival in patients with high HOXA-AS2 expression, and HOXA-AS2 was an independent prognostic factor among the normal-karyotype AMLs. |
| Pubmed ID | 32369230 |
| Year | 2020 |
| Title | Over-expression of long noncoding RNA HOXA-AS2 predicts an adverse prognosis and promotes tumorigenesis via SOX4/PI3K/AKT pathway in acute myeloid leukemia. |
External Links
| Links for HOXA-AS2 | GenBank HGNC NONCODE |
| Links for acute myeloid leukemia | OMIM COSMIC |